MA37753A3 - Composition antitumorale comprenant le composé 1-(6-{[6-(4-fluorophényl)[1,2,4]triazolo[4,3-b] pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-yléthyl)urée - Google Patents

Composition antitumorale comprenant le composé 1-(6-{[6-(4-fluorophényl)[1,2,4]triazolo[4,3-b] pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-yléthyl)urée

Info

Publication number
MA37753A3
MA37753A3 MA37753A MA37753A MA37753A3 MA 37753 A3 MA37753 A3 MA 37753A3 MA 37753 A MA37753 A MA 37753A MA 37753 A MA37753 A MA 37753A MA 37753 A3 MA37753 A3 MA 37753A3
Authority
MA
Morocco
Prior art keywords
ylethyl
benzothiazol
pyridazin
sulfanyl
triazolo
Prior art date
Application number
MA37753A
Other languages
English (en)
Other versions
MA37753B1 (fr
MA37753A2 (fr
Inventor
Jean-René Authelin
Sylvie Assadourian
Tsiala Benard
Hélène Goulaouic
Amandine Mathieu
Maria-Teresa Peracchia
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA37753A2 publication Critical patent/MA37753A2/fr
Publication of MA37753A3 publication Critical patent/MA37753A3/fr
Publication of MA37753B1 publication Critical patent/MA37753B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition antitumorale comprenant le composé 1-(6-{[6-(4-fluorophényl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-yléthyl)urée et son utilisation dans le traitement du cancer.
MA37753A 2012-07-12 2013-07-11 Composition antitumorale comprenant le composé 1-(6-{[6-(4-fluorophényl)[1,2,4]triazolo[4,3-b] pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-yléthyl)urée MA37753B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12305840 2012-07-12
PCT/EP2013/064741 WO2014009500A1 (fr) 2012-07-12 2013-07-11 Composition antitumorale comprenant le composé 1-(6-{[6-(4-fluorophényl)[1,2,4]triazolo[4,3-b] pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-yléthyl)urée

Publications (3)

Publication Number Publication Date
MA37753A2 MA37753A2 (fr) 2016-06-30
MA37753A3 true MA37753A3 (fr) 2018-05-31
MA37753B1 MA37753B1 (fr) 2019-04-30

Family

ID=48782350

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37753A MA37753B1 (fr) 2012-07-12 2013-07-11 Composition antitumorale comprenant le composé 1-(6-{[6-(4-fluorophényl)[1,2,4]triazolo[4,3-b] pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-yléthyl)urée

Country Status (25)

Country Link
US (1) US20150119391A1 (fr)
EP (1) EP2872119A1 (fr)
JP (1) JP2015525754A (fr)
KR (1) KR20150030761A (fr)
CN (1) CN104470500A (fr)
AR (1) AR091727A1 (fr)
AU (1) AU2013288676A1 (fr)
BR (1) BR112015000497A2 (fr)
CA (1) CA2878500A1 (fr)
CL (1) CL2015000074A1 (fr)
CO (1) CO7160069A2 (fr)
CR (1) CR20150005A (fr)
EA (1) EA201590199A1 (fr)
HK (1) HK1209642A1 (fr)
IL (1) IL236662A0 (fr)
IN (1) IN2015KN00075A (fr)
MA (1) MA37753B1 (fr)
MX (1) MX2015000532A (fr)
PH (1) PH12015500060A1 (fr)
SG (1) SG11201500123XA (fr)
TN (1) TN2015000011A1 (fr)
TW (1) TW201402121A (fr)
UY (1) UY34909A (fr)
WO (1) WO2014009500A1 (fr)
ZA (1) ZA201500129B (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
FR2817750B1 (fr) * 2000-12-11 2003-02-21 Sanofi Synthelabo Composition pharmaceutique de dronedarone pour administration parenterale
EA009123B1 (ru) * 2003-01-14 2007-10-26 Тева Фармасьютикал Индастриз, Лтд. Парентеральные композиции пептидов для лечения системной красной волчанки
PA8792501A1 (es) * 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
PE20091432A1 (es) * 2008-02-28 2009-10-17 Takeda Pharmaceutical Composicion farmaceutica
CN101444510B (zh) * 2008-12-31 2011-03-09 南京卡文迪许生物工程技术有限公司 含有伏立康唑的药物制剂及其制备方法
FR2941951B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.

Also Published As

Publication number Publication date
MA37753B1 (fr) 2019-04-30
WO2014009500A1 (fr) 2014-01-16
CR20150005A (es) 2015-04-06
AR091727A1 (es) 2015-02-25
IL236662A0 (en) 2015-02-26
CA2878500A1 (fr) 2014-01-16
HK1209642A1 (en) 2016-04-08
SG11201500123XA (en) 2015-02-27
BR112015000497A2 (pt) 2017-06-27
CL2015000074A1 (es) 2015-06-12
UY34909A (es) 2013-11-29
CN104470500A (zh) 2015-03-25
EA201590199A1 (ru) 2015-05-29
IN2015KN00075A (fr) 2015-07-31
KR20150030761A (ko) 2015-03-20
TN2015000011A1 (en) 2016-06-29
US20150119391A1 (en) 2015-04-30
TW201402121A (zh) 2014-01-16
CO7160069A2 (es) 2015-01-15
JP2015525754A (ja) 2015-09-07
PH12015500060A1 (en) 2015-03-02
ZA201500129B (en) 2015-12-23
AU2013288676A1 (en) 2015-02-05
MA37753A2 (fr) 2016-06-30
MX2015000532A (es) 2015-05-15
EP2872119A1 (fr) 2015-05-20

Similar Documents

Publication Publication Date Title
NI201500067A (es) Compuestos de pirrolopirimidina como inhibidores de quinasa
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
TN2016000094A1 (en) Inhibitors of bruton's tyrosine kinase.
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
MX2019010709A (es) Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
PH12018502497A1 (en) Adenosine derivatives for use in the treatment of cancer
MX2015016085A (es) Derivados de heterociclicos.
MX359664B (es) Tratamiento de cáncer de mama.
WO2015009726A3 (fr) Utilisations médicales d'agonistes de cd38
MA47356A1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
CY1116318T1 (el) Μακροκυκλικη ενωση και μεθοδοι για την παραγωγη της
SA515370253B1 (ar) مركب أميد عطري غير متجانس الحلقة يحتوي على نتروجين ثنائي الحلقة
MA37753B1 (fr) Composition antitumorale comprenant le composé 1-(6-{[6-(4-fluorophényl)[1,2,4]triazolo[4,3-b] pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-yléthyl)urée
RU2013107122A (ru) 6-ЗАМЕЩЕННЫЕ 3-АЗОЛИЛИМИДАЗО[1,2-b][1,2,4,5]ТЕТРАЗИНЫ, ПРОЯВЛЯЮЩИЕ ПРОТИВООПУХОЛЕВУЮ АКТИВНОСТЬ
BR112015013196A2 (pt) combinações de um composto inibidor de pi3k/akt com um composto inibidor de her3/egfr e métodos de uso
MA34380B1 (fr) Association antitumorale comprenant de l'ombrabuline, un dérivé de taxane et un dérivé de platine
MA38657A1 (fr) Combinaison d'un dérivé d'imidazopyridazine et d'un agent mitotique pour le traitement du cancer
UA110910C2 (uk) Карбоксамідні похідні піразолу як інгібітори тирозинкінази брутона, фармацевтична композиція на їх основі та спосіб лікування захворювань (варіанти)
NZ629459A (en) Methods for treating cancer using tor kinase inhibitor combination therapy